Amcure

Info

Amcure is a clinical-stage company developing peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.

Lead candidate AMC303 is being developed as a treatment for patients with advanced and metastatic squamous tumors, e.g. head and neck cancer, esophageal cancer, cervical cancer, and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON)